Evidence map›Paper›PMID 18855677›Full record

ReviewCurrent medicinal chemistry2008

Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening.

Ahmet Bakan, John S Lazo, Peter Wipf, Kay M Brummond, Ivet Bahar

Open access · greenAbstract readReview
In one paragraph

Review in Current medicinal chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Protein Kinases in Obesity, and the Kinase-Targeted Therapy.Advances in experimental medicine and biology · 2024
    Review
  4. Review
  5. Review
  6. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.Journal of cancer research and clinical oncology · 2022
    Review
  7. MBP-binding DARPins facilitate the crystallization of an MBP fusion protein.Acta crystallographica. Section F, Structural biology communications · 2018
    Article
  8. Crystal structure of the human dual specificity phosphatase 1 catalytic domain.Protein science : a publication of the Protein Society · 2018
    Article
  9. Article
  10. DUSPs, to MAP kinases and beyond.Cell & bioscience · 2012
    Article
  11. Review
  12. High-throughput crystallography for structural genomics.Current opinion in structural biology · 2009
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ahmet BakanDepartment of Computational Biology, School of Medicine, University of Pittsburgh, 3064 Biomedical Science Tower 3, 3501 Fifth Avenue, Pittsburgh, PA 15213, USA.
John S Lazo
Peter Wipf
Kay M Brummond
Ivet Bahar
University of Pittsburgh · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Pittsburgh Molecular Libraries Screening Center(RMI)U54MH074411 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAZO, JOHN S. · 2005 to 2008
$10.1M
TRADITIONAL AND FLUOROUS SYNTHESIS APPROACHES TO DICTYOSTATIN ANTICANCER AGENTSP01CA078039 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAZO, JOHN S. · 1998 to 2009
$9.9M
Computational Prediction of Biomolecular DynamicsR33GM068400 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAHAR, IVET · 2005 to 2007
$912k
NCATS NIH HHS UL1 TR000005NCI NIH HHS CA78039NCI NIH HHS P01 CA078039NIGMS NIH HHS R33 GM068400NIMH NIH HHS 1U54MH074411NIMH NIH HHS U54 MH074411
6 · The paper itself

Abstract

Dual-specificity phosphatases (DSPs) are important, but poorly understood, cell signaling enzymes that remove phosphate groups from tyrosine and serine/threonine residues on their substrate. Deregulation of DSPs has been implicated in cancer, obesity, diabetes, inflammation, and Alzheimer's disease. Due to their biological and biomedical significance, DSPs have increasingly become the subject of drug discovery high-throughput screening (HTS) and focused compound library development efforts. Progress in identifying selective and potent DSP inhibitors has, however, been restricted by the lack of sufficient structural data on inhibitor-bound DSPs. The shallow, almost flat, substrate binding sites in DSPs have been a major factor in hampering the rational design and the experimental development of active site inhibitors. Recent experimental and virtual HTS studies, as well as advances in molecular modeling, provide new insights into the potential mechanisms for substrate recognition and binding by this important class of enzymes. We present herein an overview of the progress, along with a brief description of applications to two types of DSPs: Cdc25 and MAP kinase phosphatase (MKP) family members. In particular, we focus on combined computational and experimental efforts for designing Cdc25B and MKP-1 inhibitors and understanding their mechanisms of interactions with their target proteins. These studies emphasize the utility of developing computational models and methods that meet the two major challenges currently faced in structure-based in silico design of lead compounds: the conformational flexibility of the target protein and the entropic contribution to the selection and stabilization of particular bound conformers.

Indexed as

AlgorithmsAmino Acid SequenceBinding Sitescdc25 PhosphatasesCombinatorial Chemistry TechniquesDrug Evaluation, PreclinicalDual Specificity Phosphatase 1Dual-Specificity PhosphatasesEnzyme InhibitorsModels, MolecularMolecular Sequence DataProtein ConformationStructure-Activity RelationshipSubstrate Specificitycdc25 PhosphatasesDual Specificity Phosphatase 1Dual-Specificity PhosphatasesEnzyme Inhibitors

Identifiers

PMID18855677
PMCPMC2764859
OpenAlexW2170066505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.